
Media Coverage
U.S. Patent for Bolt Biotherapeutics’ Boltbody™ ISAC Platform Technology is a Major Milestone in the Development of BDC-1001
ADC Review
Read MoreRandall Schatzman, Ph.D. to Lead Growth of Immune- Stimulating Antibody Conjugates at Bolt Biotherapeutics
ADC Review
Read MoreHow the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy
ADC Review
Read MoreBolt Biotherapeutics Nabs $93.5M to Push Provenge Inventor’s New Idea Deeper in the Clinic
Endpoints News
Read MorePfizer-Backed Bolt Therapeutics Strikes $93.5M Funding Round As Lead Med Hits the Clinic
Fierce Biotech
Read More
Podcasts
Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm
Business of Biotech Podcast
Listen NowCMC Considerations For In-Human Studies with Drs. Edith Perez and Nathan Ihle
Business of Biotech Podcast
Listen NowAdvances in Targeted Cancer Therapy
with Dr. Edith Perez
Empowered Patient Podcast
Posters & Publications
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Ackerman SE, et al., Nature Cancer (2020)
View NowPhase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 San Antonio Breast Cancer Symposium
View NowPhase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
View NowCovalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcγR- and TLR- signaling and enables safe systemic administration
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
View NowSystemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models
Presented at: 2020 Society for Immunotherapy of Cancer (SITC)
View NowHER2-targeting TLR 7/8 immune-stimulating antibody conjugates elicit robust myeloid activation and anti-tumor immune responses in a TLR- and FcR-dependent manner
Presented at: 2019 Society for Immunotherapy of Cancer (SITC)
View NowTLR7/8 immune stimulating antibody conjugates elicit robust myeloid activation and durable anti-tumor immunity
Presented at: 2019 American Association for Cancer Research (AACR)
View NowSystemic Immunity is Required for Effective Cancer Immunotherapy
Spitzer MH, et al. Cell (2017)
View NowAllogenic IgG Combined with Dendritic Cell Stimuli Induce Antitumor T-cell Immunity
Carmi Y, et al. Nature (2015)
View Now900 Chesapeake Drive
Redwood City, CA 94063
Phone: 650.665.9295
info@boltbio.com